GlassScriptPhysician profile
John S Adams
NPI 1003880493
$1,973.69
in general payments reported to CMS, 2019-2025
25 companies · $454 in 2025
The $454 reported for 2025 was more than what 76% of Obstetrics providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $591 · 2020: $63.87 · 2021: $105 · 2022: $224 · 2023: $177 · 2024: $359 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $990.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $990.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $520.50 | 2019 | |
| Myovant Sciences INC. | $197.06 | 2021-2022 | |
| Sage Therapeutics, LLC | $148.12 | 2024-2025 | Zurzuvae |
| Avion Pharmaceuticals | $123.38 | 2019-2023 | Balcoltra |
| Mayne Pharma Commercial LLC | $117.01 | 2021-2025 | |
| Abbott Laboratories | $104.96 | 2025 | Aveir |
| Exeltis, USA INC. | $100.88 | 2023-2024 | Slynd |
| Organon LLC | $84.74 | 2024-2025 | Nexplanon |
| Hologic Sales and Service, LLC | $63.30 | 2023-2024 | Thinprep 2000 Processor, Aptima, Myosure Tissue Removal Device |
| Pfizer INC. | $59.82 | 2022-2025 | |
| Astellas Pharma US INC | $55.82 | 2023-2025 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $50.70 | 2023 | Myfembree, Gemtesa |
| Janssen Biotech, INC. | $47.72 | 2024 | Erleada |
| Novo Nordisk INC | $44.70 | 2023-2024 | Wegovy |
| Supernus Pharmaceuticals, INC. | $42.65 | 2025 | Qelbree |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $38.35 | 2025 | |
| Ethicon US, LLC | $35.77 | 2023-2024 | Ethicon, Surgicel Nu-Knit, Stratafix |
| Pacira Pharmaceuticals Incorporated | $27.39 | 2025 | Exparel |
| C. R. Bard, INC. & Subsidiaries | $21.82 | 2024 | |
| Medtronic, INC. | $18.69 | 2025 | Interstim |
| Vertex Pharmaceuticals Incorporated | $17.90 | 2025 | |
| Abbvie INC. | $14.06 | 2021 | |
| Smith+Nephew, INC. | $14.00 | 2024 | Pico |
| Antares Pharma, INC. | $12.40 | 2020 | |
| Allergan, INC. | $11.95 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.